Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-07-22 4:18 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | CITADEL ADVISORS LLC | 3,410,764 5.3% | 3,410,764![]() (New Position) | View |
2024-07-18 5:33 pm Sale | 13D | Terns Pharmaceuticals Inc. TERN | ORBIMED ADVISORS LLC | 7,562,971 11.7% | -56,164![]() (-0.74%) | View |
2024-06-07 1:30 pm Sale | 13G | Terns Pharmaceuticals Inc. TERN | BlackRock Inc. BLK | 3,120,865 4.8% | -288,113![]() (-8.45%) | View |
2024-06-07 08:30 am Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Soleus Capital Master Fund L.P. | 3,341,120 5.2% | 3,341,120![]() (New Position) | View |
2024-03-07 4:15 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Point72 Asset Management L.P. | 3,921,226 6.3% | 3,921,226![]() (New Position) | View |
2024-02-14 8:38 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Venrock Healthcare Capital Partners III L.P. | 4,497,117 7.3% | 789,226![]() (+21.29%) | View |
2024-02-14 3:47 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Fairmount Funds Management LLC | 6,632,015 9.9% | 1,362,728![]() (+25.86%) | View |
2024-02-14 08:57 am Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Deep Track Capital LP | 6,100,000 9.87% | 2,540,000![]() (+71.35%) | View |
2024-02-13 5:21 pm Unchanged | 13G | Terns Pharmaceuticals Inc. TERN | LAV Biosciences Fund V L.P. | 2,901,566 4.7% | 0 (Unchanged) | View |
2024-02-13 11:44 am Purchase | 13G | Terns Pharmaceuticals Inc. TERN | SUVRETTA CAPITAL MANAGEMENT LLC | 5,837,126 9.5% | 2,388,851![]() (+69.28%) | View |
2024-02-09 10:05 am Sale | 13G | Terns Pharmaceuticals Inc. TERN | FMR LLC | 2,990,402 4.839% | -2,127,648![]() (-41.57%) | View |
2024-01-31 2:08 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | BlackRock Inc. BLK | 3,408,978 5.5% | 3,408,978![]() (New Position) | View |
2024-01-25 4:09 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | INTEGRATED CORE STRATEGIES (US) LLC | 3,479,630 5.6% | 3,479,630![]() (New Position) | View |
2023-10-13 3:58 pm Sale | 13G | Terns Pharmaceuticals Inc. TERN | FMR LLC | 5,118,050 8.38% | -2,260,591![]() (-30.64%) | View |
2023-10-10 09:09 am Purchase | 13G | Terns Pharmaceuticals Inc. TERN | FIL Ltd | 5,118,050 8.38% | 5,118,050![]() (New Position) | View |
2023-10-04 5:09 pm Sale | 13G | Terns Pharmaceuticals Inc. TERN | Flynn James E | 0 0% | -2,851,287![]() (Position Closed) | View |
2023-07-28 4:25 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Deep Track Capital LP | 3,560,000 6.28% | 3,560,000![]() (New Position) | View |
2023-06-27 4:32 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | MILLENNIUM MANAGEMENT LLC | 2,313,370 4.1% | 2,313,370![]() (New Position) | View |
2023-03-29 5:24 pm Unchanged | 13D | Terns Pharmaceuticals Inc. TERN | ORBIMED ADVISORS LLC | 7,619,135 13.4% | 0 (Unchanged) | View |
2023-02-14 4:06 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Venrock Healthcare Capital Partners III L.P. | 3,707,891 7.7% | 641,650![]() (+20.93%) | View |